Posts | Comments

Rapidly Expanding Manufacturing Capabilities Fuels the Growth of the Global Biologics Market

Contact Us
Nick Thomas
1147 88AVE
Delta
BC  
Canada
Phone:+1 604 800 2671
nikc@marknteladvisors.com

According to MarkNtel Advisors’ research report, “Global Biologics Market Analysis, 2021,” the market is likely to witness around 9% CAGR during 2021-26. It owes to the burgeoning prevalence of chronic diseases across the globe, mounting availability of advanced diagnosis systems, and surging government investments to enhance the healthcare sector. Further, rapidly increasing technological advancements, snowballing demand for biologics drugs, and better access to healthcare are other critical aspects likely to influence the growth of the Biologics Market across the globe.

Key Questions Answered in the Study
1. What are the current and future trends in the Global Biologics market?
2. How has the industry been evolving in terms of geography and services adoption?
3. How has the competition been shaping across the countries, followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Global Biologics market?
5. What is the customer orientation, purchase behavior, and expectations from the Global Biologics market service providers across various regions?

Get a sample copy of the market analysis: https://www.marknteladvisors.com/query/request-sample/global-biologics-market.html

Impact of COVID-19 Pandemic
The outbreak of the COVID-19 pandemic has resulted in the delaying diagnoses & treatment process and put a halt to clinical trials. Thus, the pandemic has slightly affected the market. However, surging demand and production of biologics during the pandemic have positively influenced market growth. Additionally, continuous manufacturing for biologics due to the burgeoning demand for these drugs also augments the manufacturing capacity of biologics.

“Global Biologics Market Analysis, 2021” provides comprehensive, qualitative, and quantitative insights on the market potential, key factors impacting the market growth, hotspots, and opportunities available for Biologics providers across the globe. Moreover, the report also encompasses the key strategic imperatives for competitors’ success and strategic factorial indexing to measure their capabilities on 16 parameters, which will help companies formulate ‘Go to Market’ strategies and identify the blue ocean for their offerings.

Infectious Diseases Exhibits Fastest Growth
Based on Therapeutic Application, the market bifurcates into Oncology, Infectious Disease, Autoimmune Disease, Diabetes, Metabolic disorders, Inflammatory Bowel Diseases, Respiratory Disorders, Neurological Disorders, Cardiovascular Disorder, Musculoskeletal Disorders, and Ophthalmic Disorders. Infectious Disease is more likely to grow substantially in the Global Biologics market during 2021-26. The segment growth owes to the mounting viral diseases leading to increase investments for the development of drugs that are beneficial for the treatment of infectious diseases. Therefore, the Infectious Disease segment is likely to contribute to the overall market growth in the forecast period, reveals MarkNtel Advisors in their research report, “Global Biologics Market Analysis, 2021.”

According to MarkNtel Advisors, the major leading players in the Global Biologics Market are Abbive Inc., Amgen Inc., F. Hoffman La Roche, Samsung Electronics, Merck & Co., AstraZeneca Plc., Bristol-Myers Squibb, Novartis, Pfizer, and Sanofi.

Market Segmentation:
1. By Therapeutic Application (Oncology, Infectious Disease, Autoimmune Disease, Diabetes, Metabolic disorders, Inflammatory Bowel Diseases, Respiratory Disorders, Neurological Disorders, Cardiovascular Disorder, Musculoskeletal Disorders, Ophthalmic Disorders, Others)
2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
3. By Manufacturing (Outsource, In-house)
4. By Product/Drug Class (Recombinant therapeutic Products, Monoclonal Antibodies, Hormones, Cytokines, Enzymes, Blood & Blood Components, Cellular & Gene Therapy, Vaccines, Oligonucleotides)
5. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
6. By Country (U.S, Canada, Brazil, Argentina, Mexico, Germany, France, The U.K, Spain, Italy, China, India, Japan, Australia, UAE, Saudi Arabia)
7. By Competitors (Abbive Inc., Amgen Inc., F. Hoffman La Roche, Samsung Electronics, Merck & Co., AstraZeneca Plc, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi)

Leave a Reply